Wikipedia -WSS

Wikipedia

author：focus 2025-09-05 13:47:44 - browse：649

Jakub Porzycki/NurPhoto via AP

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hello, everyone. Damian here with the fallout from Pfizer’s downbeat update, a new entrant in obesity research, and an orthogonal CRISPR business.

The need-to-know this morning

Apellis Pharmaceuticals said a European advisory committee is expected to recommend against the approval of Syfovre, its eye drug for a common form of blindness. The company plans to appeal the negative ruling.
Sage Therapeutics and Biogen announced the commercial launch of Zurzuvae, an oral treatment for women with postpartum depression.
Merck and Moderna reported three-year follow-up data on their mRNA-based immunotherapy for advanced melanoma. Phase 3 studies are underway.
The FDA accepted Amgen’s marketing application for tarlatamab, a bispecific antibody to treat advanced small cell lung cancer. The approval decision date is June 12, 2024.

Is it time to worry about Moderna?

Yesterday’s news that Pfizer is expecting to sell far fewer Covid-19 vaccines than Wall Street expected sent shares of Moderna down as much as 6% on fears that the company could be in for a painful revision of its own.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Why age limits for politicians are a terrible idea

leisure time

explore

WSS

Flu vaccine offering decent levels of protection this winter, new data show

Liquid biopsy for lung cancer is launched by Delfi

Scientists unlock the key to scar

An inside look at PIPEs, biotech's buzzy new financing tool

Histogen: Failed biotech offers rare public look inside

The future of health care in the House

explore

Wikipedia

The need-to-know this morning

Is it time to worry about Moderna?

hotspot

Medical leaders decry Supreme Court decision on affirmative action

RSV vaccines may be linked to small increased risk of developing GBS

Cancer drug shortages should be causing more outrage

Biotech companies concerned about China biosecurity crackdown

Wildfire smoke exposes gaps in outdoor worker protections

ALS groups 'won't be played again' by the FDA, drug sponsors

Drug repurposing or repositioning? The language matters

Kenai launches with $82 million for Parkinson’s stem cell therapy

Affirmative action in medical school literally saved lives

Medical device lobby: We're tired of waiting on Medicare coverage

focus

Phenylephrine and the overlooked value of the placebo effect

Biotech companies concerned about China biosecurity crackdown

FDA authorizes Novavax’s updated Covid

Bill would stop addiction treatment from triggering child abuse inquiry

In search for therapies for solid tumors, companies turn to claudin

How to fix the rural physician shortage in the U.S.

knowledge

leisure time

explore

Wikipedia